OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
PHILADELPHIA, May 02, 2017 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 9, 2017, at 8:30 a.m. EDT to discuss corporate and financial results for the quarter that ended March 31, 2017.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 13840065. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 13840065, or by visiting the “Investors” section at www.sparktx.com.
About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.
Investor Contact: Ryan Asay [email protected] (215) 239-6424 Media Contact: Monique da Silva [email protected] 215-282-7470
